PBAC's latest decision on Lanthanum carbonate hydrate: Deferred (2008). Considered for Management of hyperphosphataemia in patients with chronic kidney disease on dialysis whose serum phosphate is not controlled on other products and where serum phosphate is greater than 1.6 mmol per L or the serum calcium times phosphate product is greater than 4.0.
PBAC outcome
Deferred
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2008
Submissions
1
2008 → 2008
Eligible population
Patients with chronic kidney disease on dialysis whose serum phosphate is not controlled on other products and where serum phosphate is greater than 1.6 mmol per L or the serum calcium times phosphate product is greater than 4.0
Therapy area
Endocrinology
Line of therapy
Any
Evidence base
RCT
Primary endpoint
Phosphate control
Key trials
LAM-IV-301, LAM-IV-303, LAM-IV-307, SPD405-310, DCOR, RIND, CARE, CARE-2, Treat to Goal
Comparator
sevelamer hydrochloride
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis presented; no ICER calculated by design